Journals / Türk Biyokimya Dergisi / 2019 / Cilt: 44 - Sayı: 1

SAHA modulates cell proliferation, colony forming and epithelial-mesenchymal transition in CCA cells

SAHA, CCA hücrelerinde hücre proliferasyonunu, koloni oluşumunu ve epitelyal mezenkimal geçişi modüle eder

Pages
70–77
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: It was found that SAHA significantly inhibits cell viability, proliferation and migration of TFK-1 cells, accompanied by reversing of EMT markers.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Therapeutic options for advanced cholangiocarcinoma (CCA) are limited and ineffective due to the largely incomplete understanding of the molecular pathogenesis of this deadly tumor.
📊
Key Findings & Data:Results: It was found that SAHA significantly inhibits cell viability, proliferation and migration of TFK-1 cells, accompanied by reversing of EMT markers.
💡
Conclusion & Impact:However, future studies are needed to evaluate the clinical applicability of SAHA as a part of the chemotherapeutic regimen for CCA.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Therapeutic options for advanced cholangiocarcinoma (CCA) are limited and ineffective due to the largely incomplete understanding of the molecular pathogenesis of this deadly tumor. So that, we planned to investigate epigenetic regulation of epithelial-mesenchymal transition (EMT) in cholangiocarcinoma cell line by applying Suberoylanilide hydroxamic acid (SAHA). We studied the effect of SAHA on cell proliferation, colony forming, migration and protein level of E-cadherin (E-cad) as an epithelial EMT marker, N-cadherin (N-cad) and Vimentin (Vim), as a mesenchymal markers of EMT, in human CCA cell line. Materials and methods: Cell proliferation and migration measurements were performed by flow cytometry and wound healing assay, respectively. E-cad, N-cad and Vim protein levels were determined by Western blot analysis. Results: It was found that SAHA significantly inhibits cell viability, proliferation and migration of TFK-1 cells, accompanied by reversing of EMT markers. SAHA, upregulated protein level of E-cad, while downregulated the protein levels of N-cad and Vimentin. Conclusions: SAHA treatment may bebeneficial for CCA patients and SAHA might be a potential therapeutic agent for the treatment of CCA. However, future studies are needed to evaluate the clinical applicability of SAHA as a part of the chemotherapeutic regimen for CCA.

Özet

Giriş: İlerlemiş kolanjiyokarsinoma (CCA) için tedavi seçenekleri sınırlıdır ve bu ölümcül tümörün moleküler patogenezinin büyük ölçüde anlaşılamaması nedeniyle etkisizdir. Böylece, suberoilanilid hidroksamik asit (SAHA) uygulayarak kolanjiokarsinoma hücre hattındaki epitelyal mezenkimal geçişin (EMT) epigenetik düzenlenmesini araştırmayı planladık. İnsan CCA hücrelerinde; SAHA’nın hücre proliferasyonuna, koloni oluşumuna, migrasyona ve epitelyal belirteç olan E-kaderin (E-kad) protein seviyesi, mezenkimal belirteç olan N-kaderin (N-kad) ve Vimentin (Vim) protein seviyesine olan etkisini araştırdık. Materyal ve metod: Hücre canlılığı ve hücre göçü ölçümleri sırasıyla, flow sitometri ve yara kapanması testi ile gerçekleştirildi. E-kad, N-kad ve Vim protein seviyeleri Western blot analizi ile belirlendi. Bulgular: SAHA’nın, EMT belirteçlerini tersine çevrilmesi ile birlikte, hücre canlılığını, hücre proliferasyonunu ve TFK-1 hücrelerinin migrasyonunu önemli ölçüde inhibe ettiği bulundu. SAHA E-kad protein seviyesini artırırken, N-kad ve Vim protein seviyesini azaltmıştır. Sonuç: SAHA tedavisi CCA hastaları için yararlı olabilir ve SAHA CCA tedavisinde potansiyel bir terapötik ajan olabilir. Bununla birlikte, CCA için kemoterapötik tedavinin bir parçası olarak SAHA’nın klinik uygulanabilirliğini değerlendirmek için gelecekteki çalışmalara ihtiyaç vardır.

🔖

Cite This Article

ÖZEL, M., BAŞKOL, G., UÇAR, Ç., DOĞRU, B. N., YÜKSEK, E. H., GÜNEŞ, F., BAŞKOL, M. (2022). SAHA modulates cell proliferation, colony forming and epithelial-mesenchymal transition in CCA cells. Türk Biyokimya Dergisi, Cilt: 44 - Sayı: 1, 70–77. https://ajindex.com/articles/620856

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014;383:2168–79
  2. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013;145:1215–29
  3. Vaquero J, Guedj N, Clapéron A, Nguyen Ho-Bouldoires TH, Paradis V, Fouassier L. Epithelial-mesenchymal transition in cholangiocarcinoma: from clinical evidence to regulatory networks. J Hepatol 2017;66:424–41
  4. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelialmesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178–96
  5. Santamaria PG, Moreno-Bueno G, Portillo F, Cano A. EMT: present and future in clinical oncology. Mol Oncol 2017;11:718–38
  6. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420–8
  7. Yamada D, Kobayashi S, Wada H, Kawamoto K, Marubashi S, Eguchi H, et al. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer 2013;49:1725–40
  8. Ronnekleiv-Kelly SM, Sharma A, Ahuja N. Epigenetic therapy and chemosensitization in solid malignancy. Cancer Treat Rev 2017;55:200–8
  9. Gallagher SJ, Shklovskaya E, Hersey P. Epigenetic modulation in cancer immunotherapy. Curr Opin Pharmacol 2017;35:48–56
  10. Mazzone R, Zwergel C, Mai A, Valente S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin Epigenetics 2017;9:59
  11. Richters A, Koehler AN. Epigenetic modulation using small molecules – targeting histone acetyltransferases in disease. Curr Med Chem 2017;24:4121–50
  12. Rius M, Lyko F. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene 2012;31:4257–65
  13. He JC, Yao W, Wang JM, Schemmer P, Yang Y, Liu Y, et al. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors. Oncotarget 2016;7:75441
  14. Sriraksa R, Limpaiboon T. Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma – cell line findings. Asian Pac J Cancer Prev 2013;14:2503–8
  15. Hibino S, Saito Y, Muramatsu T, Otani A, Kasai Y, Kimura M, et al. Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumorsuppressor microRNAs in human cancer cells. Oncogenesis 2014;3:e104
  16. Yamagishi M, Uchimaru K. Targeting EZH2 in cancer therapy. Curr Opin Oncol 2017;29:375–81
  17. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, MorenoB